RENO, NV, United States, via ETELIGIS INC., 12/19/2014 – – The Company (OTC Pink: LLBO) (PINKSHEETS: LLBO) is pleased to announce that Depository Trust Company’s (DTCC) chill has been removed and the Company’s common stock is once again tradable on both the buy and sell side on OTC Pink.
Jim Holmes, Company CEO said “Lifeline will focus on supporting its major investment in Cyrcadia Health (formerly named First Warning Systems) and assisting, as we can, to increase value. Lifeline holds the proprietary patents to the detection of cancerous and precancerous conditions in a breast; analyzing thermal data; methods of collection and systems for analyzing data based on breast surface temperature to determine suspect conditions. Lifeline is a principal shareholder of Cyrcadia with whom we licensed to further develop and market this breast cancer technology”.
Holmes went on to say that, “Lifeline will explore other prospective applications and opportunities of this patented technology. Other business opportunities will be considered.” Additional information about Lifeline can be found at www.lbti.com (which is being updated; also on OTC Markets under Lifeline’s symbol: LLBO).
About Cyrcadia, Inc. (formerly named First Warning Systems, Inc.):
Cyrcadia Health (“CH”) continues to develop the base technology covered by the Lifeline patented technology. A current final, limited clinical trial is being prepared and is expected to commence in coming months. The trial is expected to be completed in three to four months once it is commenced. CH when completed, a CEMark will be obtained, allowing marketing outside the US; an FDA 510(k) will be submitted. The 510(k), when cleared, allows CH to market in the US.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company’s product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
Lifeline BioTechnologies, Inc.
Information at: Info
SOURCE: Lifeline BioTechnologies, Inc.